{"pmid":32198291,"title":"Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved alpha-ketoamide inhibitors.","text":["Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved alpha-ketoamide inhibitors.","The COVID-19 pandemic caused by SARS-CoV-2 is a global health emergency. An attractive drug target among coronaviruses is the main protease (M(pro), 3CL(pro)), due to its essential role in processing the polyproteins that are translated from the viral RNA. We report the X-ray structures of the unliganded SARS-CoV-2 M(pro) and its complex with an alpha-ketoamide inhibitor. This was derived from a previously designed inhibitor but with the P3-P2 amide bond incorporated into a pyridone ring to enhance the half-life of the compound in plasma. Based on the structure, we developed the lead compound into a potent inhibitor of the SARS-CoV-2 M(pro) The pharmacokinetic characterization of the optimized inhibitor reveals a pronounced lung tropism and suitability for administration by the inhalative route.","Science","Zhang, Linlin","Lin, Daizong","Sun, Xinyuanyuan","Curth, Ute","Drosten, Christian","Sauerhering, Lucie","Becker, Stephan","Rox, Katharina","Hilgenfeld, Rolf","32198291"],"abstract":["The COVID-19 pandemic caused by SARS-CoV-2 is a global health emergency. An attractive drug target among coronaviruses is the main protease (M(pro), 3CL(pro)), due to its essential role in processing the polyproteins that are translated from the viral RNA. We report the X-ray structures of the unliganded SARS-CoV-2 M(pro) and its complex with an alpha-ketoamide inhibitor. This was derived from a previously designed inhibitor but with the P3-P2 amide bond incorporated into a pyridone ring to enhance the half-life of the compound in plasma. Based on the structure, we developed the lead compound into a potent inhibitor of the SARS-CoV-2 M(pro) The pharmacokinetic characterization of the optimized inhibitor reveals a pronounced lung tropism and suitability for administration by the inhalative route."],"journal":"Science","authors":["Zhang, Linlin","Lin, Daizong","Sun, Xinyuanyuan","Curth, Ute","Drosten, Christian","Sauerhering, Lucie","Becker, Stephan","Rox, Katharina","Hilgenfeld, Rolf"],"date":"2020-03-22T11:00:00Z","year":2020,"_id":"32198291","week":"202012|Mar 16 - Mar 22","doi":"10.1126/science.abb3405","source":"PubMed","locations":["plasma"],"topics":["Mechanism","Treatment"],"weight":1,"_version_":1661900078756921344,"score":6.926904,"similar":[{"pmid":32194944,"pmcid":"PMC7062204","title":"Prediction of the SARS-CoV-2 (2019-nCoV) 3C-like protease (3CL (pro)) structure: virtual screening reveals velpatasvir, ledipasvir, and other drug repurposing candidates.","text":["Prediction of the SARS-CoV-2 (2019-nCoV) 3C-like protease (3CL (pro)) structure: virtual screening reveals velpatasvir, ledipasvir, and other drug repurposing candidates.","We prepared the three-dimensional model of the SARS-CoV-2 (aka 2019-nCoV) 3C-like protease (3CL (pro)) using the crystal structure of the highly similar (96% identity) ortholog from the SARS-CoV. All residues involved in the catalysis, substrate binding and dimerisation are 100% conserved. Comparison of the polyprotein PP1AB sequences showed 86% identity. The 3C-like cleavage sites on the coronaviral polyproteins are highly conserved. Based on the near-identical substrate specificities and high sequence identities, we are of the opinion that some of the previous progress of specific inhibitors development for the SARS-CoV enzyme can be conferred on its SARS-CoV-2 counterpart. With the 3CL (pro) molecular model, we performed virtual screening for purchasable drugs and proposed 16 candidates for consideration. Among these, the antivirals ledipasvir or velpatasvir are particularly attractive as therapeutics to combat the new coronavirus with minimal side effects, commonly fatigue and headache. The drugs Epclusa (velpatasvir/sofosbuvir) and Harvoni (ledipasvir/sofosbuvir) could be very effective owing to their dual inhibitory actions on two viral enzymes.","F1000Res","Chen, Yu Wai","Yiu, Chin-Pang Bennu","Wong, Kwok-Yin","32194944"],"abstract":["We prepared the three-dimensional model of the SARS-CoV-2 (aka 2019-nCoV) 3C-like protease (3CL (pro)) using the crystal structure of the highly similar (96% identity) ortholog from the SARS-CoV. All residues involved in the catalysis, substrate binding and dimerisation are 100% conserved. Comparison of the polyprotein PP1AB sequences showed 86% identity. The 3C-like cleavage sites on the coronaviral polyproteins are highly conserved. Based on the near-identical substrate specificities and high sequence identities, we are of the opinion that some of the previous progress of specific inhibitors development for the SARS-CoV enzyme can be conferred on its SARS-CoV-2 counterpart. With the 3CL (pro) molecular model, we performed virtual screening for purchasable drugs and proposed 16 candidates for consideration. Among these, the antivirals ledipasvir or velpatasvir are particularly attractive as therapeutics to combat the new coronavirus with minimal side effects, commonly fatigue and headache. The drugs Epclusa (velpatasvir/sofosbuvir) and Harvoni (ledipasvir/sofosbuvir) could be very effective owing to their dual inhibitory actions on two viral enzymes."],"journal":"F1000Res","authors":["Chen, Yu Wai","Yiu, Chin-Pang Bennu","Wong, Kwok-Yin"],"date":"2020-03-21T11:00:00Z","year":2020,"_id":"32194944","week":"202012|Mar 16 - Mar 22","doi":"10.12688/f1000research.22457.1","keywords":["2019-nCoV","3C-like protease","COVID-19","HCV","Hepatitis C virus","SARS","antiviral","coronavirus","drug repurpose","ledipasvir","molecular modelling","velpatasvir","virtual screening"],"source":"PubMed","topics":["Treatment"],"weight":1,"_version_":1661818360771379200,"score":259.22467},{"pmid":32181901,"title":"A guideline for homology modeling of the proteins from newly discovered betacoronavirus, 2019 novel coronavirus (2019-nCoV).","text":["A guideline for homology modeling of the proteins from newly discovered betacoronavirus, 2019 novel coronavirus (2019-nCoV).","During an outbreak of respiratory diseases including atypical pneumonia in Wuhan, a previously unknown beta-coronavirus was detected in patients. The newly discovered coronavirus is similar to some beta-coronaviruses found in bats, but different from previously known SARS-CoV and MERS-CoV. High sequence identities and similarities between 2019-nCoV and SARS-CoV was found. In this work, we searched the homologous templates of all nonstructural and structural proteins of 2019-nCoV. Among the nonstructural proteins, the leader protein (nsp1), the papain-like protease (nsp3), the nsp4, the 3C-like protease (nsp5), the nsp7, the nsp8, the nsp9, the nsp10, the RNA-directed RNA polymerase (nsp12), the helicase (nsp13), the guanine-N7 methyltransferase (nsp14), the uridylate-specific endoribonuclease (nsp15), the 2'-O-methyltransferase (nsp16), and the ORF7a protein could be built on the basis of homology templates. Among the structural proteins, the spike protein (S-protein), the envelope protein (E-protein), and the nucleocapsid protein (N-protein) can be constructed based on the crystal structures of the proteins from SARS-CoV. It is known that PL-Pro, 3CL-Pro, and RdRp are important targets for design antiviral drugs against 2019-nCoV. And S protein is critical target candidate for inhibitor screening or vaccine design against 2019-nCoV because coronavirus replication is initiated by the binding of S protein to cell surface receptors. It is believed that these proteins should be useful for further structure-based virtual screening and related computer-aided drug development and vaccine design. This article is protected by copyright. All rights reserved.","J Med Virol","Dong, Shengjie","Sun, Jiachen","Mao, Zhuo","Wang, Lu","Lu, Yi-Lin","Li, Jiesen","32181901"],"abstract":["During an outbreak of respiratory diseases including atypical pneumonia in Wuhan, a previously unknown beta-coronavirus was detected in patients. The newly discovered coronavirus is similar to some beta-coronaviruses found in bats, but different from previously known SARS-CoV and MERS-CoV. High sequence identities and similarities between 2019-nCoV and SARS-CoV was found. In this work, we searched the homologous templates of all nonstructural and structural proteins of 2019-nCoV. Among the nonstructural proteins, the leader protein (nsp1), the papain-like protease (nsp3), the nsp4, the 3C-like protease (nsp5), the nsp7, the nsp8, the nsp9, the nsp10, the RNA-directed RNA polymerase (nsp12), the helicase (nsp13), the guanine-N7 methyltransferase (nsp14), the uridylate-specific endoribonuclease (nsp15), the 2'-O-methyltransferase (nsp16), and the ORF7a protein could be built on the basis of homology templates. Among the structural proteins, the spike protein (S-protein), the envelope protein (E-protein), and the nucleocapsid protein (N-protein) can be constructed based on the crystal structures of the proteins from SARS-CoV. It is known that PL-Pro, 3CL-Pro, and RdRp are important targets for design antiviral drugs against 2019-nCoV. And S protein is critical target candidate for inhibitor screening or vaccine design against 2019-nCoV because coronavirus replication is initiated by the binding of S protein to cell surface receptors. It is believed that these proteins should be useful for further structure-based virtual screening and related computer-aided drug development and vaccine design. This article is protected by copyright. All rights reserved."],"journal":"J Med Virol","authors":["Dong, Shengjie","Sun, Jiachen","Mao, Zhuo","Wang, Lu","Lu, Yi-Lin","Li, Jiesen"],"date":"2020-03-18T11:00:00Z","year":2020,"_id":"32181901","week":"202012|Mar 16 - Mar 22","doi":"10.1002/jmv.25768","keywords":["2019-nCoV","BLAST algorithm","CLUSTAL analysis","Coronavirus","Homology modeling","MERS-CoV","SARS-CoV","Sequence alignment"],"source":"PubMed","locations":["Wuhan"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Mechanism"],"weight":1,"_version_":1661542091970314241,"score":212.6507},{"pmid":32167173,"title":"The potential chemical structure of anti-SARS-CoV-2 RNA-dependent RNA polymerase.","text":["The potential chemical structure of anti-SARS-CoV-2 RNA-dependent RNA polymerase.","An outbreak of corona virus disease 2019 (COVID-19) occurred in Wuhan and it has rapidly spread to almost all parts of the world. For coronaviruses, RNA-dependent RNA polymerase (RdRp) is an important protease that catalyze the replication of RNA from RNA template and is an attractive therapeutic target. In this study, we screened these chemical structures from traditional Chinese medicinal compounds proven to show anti-viral activity in SARS-CoV and the similar chemical structures through a molecular docking study to target RdRp of SARS-CoV-2, SARS-CoV and MERS-CoV. We found that theaflavin has a lower idock score in the catalytic pocket of RdRp in SARS-CoV-2 (-9.11 kcal/mol), SARS-CoV (-8.03 kcal/mol) and MERS-CoV (-8.26 kcal/mol) from idock. To confirm the result, we discovered that theaflavin has a lower binding energy of -8.8 kcal/mol when it docks in the catalytic pocket of SARS-CoV-2 RdRp by using the Blind Docking server. Regarding contact modes, hydrophobic interactions contribute significantly in binding and additional hydrogen bonds were found between theaflavin and RdRp. Moreover, one pi-cation interaction was formed between theaflavin and Arg553 from the Blind Docking server. Our results suggest that theaflavin could be potential SARS-CoV-2 RdRp inhibitor for further study. This article is protected by copyright. All rights reserved.","J Med Virol","Lung, Jrhau","Lin, Yu-Shih","Yang, Yao-Hsu","Chou, Yu-Lun","Shu, Li-Hsin","Cheng, Yu-Ching","Liu, Hung Te","Wu, Ching-Yuan","32167173"],"abstract":["An outbreak of corona virus disease 2019 (COVID-19) occurred in Wuhan and it has rapidly spread to almost all parts of the world. For coronaviruses, RNA-dependent RNA polymerase (RdRp) is an important protease that catalyze the replication of RNA from RNA template and is an attractive therapeutic target. In this study, we screened these chemical structures from traditional Chinese medicinal compounds proven to show anti-viral activity in SARS-CoV and the similar chemical structures through a molecular docking study to target RdRp of SARS-CoV-2, SARS-CoV and MERS-CoV. We found that theaflavin has a lower idock score in the catalytic pocket of RdRp in SARS-CoV-2 (-9.11 kcal/mol), SARS-CoV (-8.03 kcal/mol) and MERS-CoV (-8.26 kcal/mol) from idock. To confirm the result, we discovered that theaflavin has a lower binding energy of -8.8 kcal/mol when it docks in the catalytic pocket of SARS-CoV-2 RdRp by using the Blind Docking server. Regarding contact modes, hydrophobic interactions contribute significantly in binding and additional hydrogen bonds were found between theaflavin and RdRp. Moreover, one pi-cation interaction was formed between theaflavin and Arg553 from the Blind Docking server. Our results suggest that theaflavin could be potential SARS-CoV-2 RdRp inhibitor for further study. This article is protected by copyright. All rights reserved."],"journal":"J Med Virol","authors":["Lung, Jrhau","Lin, Yu-Shih","Yang, Yao-Hsu","Chou, Yu-Lun","Shu, Li-Hsin","Cheng, Yu-Ching","Liu, Hung Te","Wu, Ching-Yuan"],"date":"2020-03-14T11:00:00Z","year":2020,"_id":"32167173","week":"202011|Mar 09 - Mar 15","doi":"10.1002/jmv.25761","keywords":["RNA-dependent RNA polymerase","SARS-CoV-2","theaflavin","traditional Chinese medicinal compounds"],"source":"PubMed","locations":["Chinese","RdRp","Wuhan"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Mechanism"],"weight":1,"_version_":1661359647951421441,"score":190.39183},{"pmid":32162456,"title":"Rapid Identification of Potential Inhibitors of SARS-CoV-2 Main Protease by Deep Docking of 1.3 Billion Compounds.","text":["Rapid Identification of Potential Inhibitors of SARS-CoV-2 Main Protease by Deep Docking of 1.3 Billion Compounds.","The recently emerged 2019 Novel Coronavirus (SARS-CoV-2) and associated COVID-19 disease cause serious or even fatal respiratory tract infection and yet no approved therapeutics or effective treatment is currently available to effectively combat the outbreak. This urgent situation is pressing the world to respond with the development of novel vaccine or a small molecule therapeutics for SARS-CoV-2. Along these efforts, the structure of SARS-CoV-2 main protease (Mpro) has been rapidly resolved and made publicly available to facilitate global efforts to develop novel drug candidates. Recently, our group has developed a novel deep learning platform - Deep Docking (DD) which provides fast prediction of docking scores of Glide (or any other docking program) and, hence, enables structure-based virtual screening of billions of purchasable molecules in a short time. In the current study we applied DD to all 1.3 billion compounds from ZINC15 library to identify top 1,000 potential ligands for SARS-CoV-2 Mpro protein. The compounds are made publicly available for further characterization and development by scientific community.","Mol Inform","Ton, Anh-Tien","Gentile, Francesco","Hsing, Michael","Ban, Fuqiang","Cherkasov, Artem","32162456"],"abstract":["The recently emerged 2019 Novel Coronavirus (SARS-CoV-2) and associated COVID-19 disease cause serious or even fatal respiratory tract infection and yet no approved therapeutics or effective treatment is currently available to effectively combat the outbreak. This urgent situation is pressing the world to respond with the development of novel vaccine or a small molecule therapeutics for SARS-CoV-2. Along these efforts, the structure of SARS-CoV-2 main protease (Mpro) has been rapidly resolved and made publicly available to facilitate global efforts to develop novel drug candidates. Recently, our group has developed a novel deep learning platform - Deep Docking (DD) which provides fast prediction of docking scores of Glide (or any other docking program) and, hence, enables structure-based virtual screening of billions of purchasable molecules in a short time. In the current study we applied DD to all 1.3 billion compounds from ZINC15 library to identify top 1,000 potential ligands for SARS-CoV-2 Mpro protein. The compounds are made publicly available for further characterization and development by scientific community."],"journal":"Mol Inform","authors":["Ton, Anh-Tien","Gentile, Francesco","Hsing, Michael","Ban, Fuqiang","Cherkasov, Artem"],"date":"2020-03-13T11:00:00Z","year":2020,"_id":"32162456","week":"202011|Mar 09 - Mar 15","doi":"10.1002/minf.202000028","keywords":["COVID-19","Deep learning","SARS-CoV-2","protease inhibitors","virtual screening"],"source":"PubMed","locations":["ZINC15"],"topics":["Treatment"],"weight":1,"_version_":1661359647894798338,"score":180.17445},{"pmid":32152082,"title":"Compounds with therapeutic potential against novel respiratory 2019 coronavirus.","text":["Compounds with therapeutic potential against novel respiratory 2019 coronavirus.","Currently, the expansion of the novel human respiratory coronavirus (known as: SARS-CoV-2, COVID-2019, or 2019-nCoV) has stressed the need for therapeutic alternatives to alleviate and stop this new epidemic. The previous epidemics of high-morbidity human coronaviruses, such as the acute respiratory syndrome coronavirus (SARS-CoV) in 2003, and the Middle East respiratory syndrome corona virus (MERS-CoV) in 2012, prompted the characterization of compounds that could be potentially active against the currently emerging novel coronavirus SARS-CoV-2. The most promising compound is remdesivir (GS-5734), a nucleotide analog prodrug currently in clinical trials for treating Ebola virus infections. Remdesivir inhibited the replication of SARS-CoV and MERS-CoV in tissue cultures, and it displayed efficacy in non-human animal models. In addition, a combination of the human immunodeficiency virus type 1 (HIV-1) protease inhibitors, lopinavir/ritonavir, and interferon beta (LPV/RTV-INFb) were shown to be effective in patients infected with SARS-CoV. LPV/RTV-INFb also improved clinical parameters in marmosets and mice infected with MERS-CoV. Remarkably, the therapeutic efficacy of remdesivir appeared to be superior to that of LPV/RTV-INFb against MERS-CoV in a transgenic humanized mice model. The relatively high mortality rates associated with these three novel human coronavirus infections, SARS-CoV, MERS-CoV, and SARS-CoV-2, has suggested that pro-inflammatory responses might play a role in the pathogenesis. It remains unknown whether the generated inflammatory state should be targeted. Therapeutics that target the coronavirus alone might not be able to reverse highly pathogenic infections. This minireview aimed to provide a summary of therapeutic compounds that showed potential in fighting SARS-CoV-2 infections.","Antimicrob Agents Chemother","Martinez, Miguel Angel","32152082"],"abstract":["Currently, the expansion of the novel human respiratory coronavirus (known as: SARS-CoV-2, COVID-2019, or 2019-nCoV) has stressed the need for therapeutic alternatives to alleviate and stop this new epidemic. The previous epidemics of high-morbidity human coronaviruses, such as the acute respiratory syndrome coronavirus (SARS-CoV) in 2003, and the Middle East respiratory syndrome corona virus (MERS-CoV) in 2012, prompted the characterization of compounds that could be potentially active against the currently emerging novel coronavirus SARS-CoV-2. The most promising compound is remdesivir (GS-5734), a nucleotide analog prodrug currently in clinical trials for treating Ebola virus infections. Remdesivir inhibited the replication of SARS-CoV and MERS-CoV in tissue cultures, and it displayed efficacy in non-human animal models. In addition, a combination of the human immunodeficiency virus type 1 (HIV-1) protease inhibitors, lopinavir/ritonavir, and interferon beta (LPV/RTV-INFb) were shown to be effective in patients infected with SARS-CoV. LPV/RTV-INFb also improved clinical parameters in marmosets and mice infected with MERS-CoV. Remarkably, the therapeutic efficacy of remdesivir appeared to be superior to that of LPV/RTV-INFb against MERS-CoV in a transgenic humanized mice model. The relatively high mortality rates associated with these three novel human coronavirus infections, SARS-CoV, MERS-CoV, and SARS-CoV-2, has suggested that pro-inflammatory responses might play a role in the pathogenesis. It remains unknown whether the generated inflammatory state should be targeted. Therapeutics that target the coronavirus alone might not be able to reverse highly pathogenic infections. This minireview aimed to provide a summary of therapeutic compounds that showed potential in fighting SARS-CoV-2 infections."],"journal":"Antimicrob Agents Chemother","authors":["Martinez, Miguel Angel"],"date":"2020-03-11T11:00:00Z","year":2020,"_id":"32152082","week":"202011|Mar 09 - Mar 15","doi":"10.1128/AAC.00399-20","source":"PubMed","topics":["Treatment"],"weight":1,"_version_":1661359647833980928,"score":170.92842}]}